Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 3/20 | 0.55 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | PDE2A | O00408 | 3/20 | 0.43 |
| ▸ | PDE1A | P54750 | 1/20 | 0.43 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.43 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516430 | 0.81 | PDE2A (0.44) | ADORA2BADORA2AALDH1A1LMNACYP3A4 | |
| Theobromine SCHEMBL2328879 | 0.80 | CYP3A4 (0.66) | ADORA2BADORA2AALDH1A1LMNACYP3A4 | |
| SCHEMBL6381402 | 0.79 | ADORA2B (0.36) | ADORA2BADORA2APDE2APDE1APDE1B | |
| SCHEMBL22521882 | 0.79 | ADORA2B (0.54) | ADORA2BADORA2AALDH1A1LMNACYP3A4 | |
| SCHEMBL21935452 | 0.79 | ADORA2B (0.54) | ADORA2BADORA2AALDH1A1LMNACYP3A4 | |
| SCHEMBL3182825 | 0.79 | ADORA2B (0.54) | ADORA2BADORA2AALDH1A1LMNACYP3A4 | |
| SCHEMBL19112343 | 0.77 | ADORA2B (0.51) | ADORA2BADORA2AALDH1A1LMNACYP3A4 | |
| SCHEMBL5461564 | 0.77 | ADORA2B (0.51) | ADORA2BADORA2AALDH1A1LMNACYP3A4 | |
| SCHEMBL516431 | 0.77 | ADORA2B (0.55) | ADORA2BADORA2AALDH1A1LMNACYP3A4 | |
| SCHEMBL15003910 | 0.75 | ADORA2B (0.50) | ADORA2BADORA2AALDH1A1LMNACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 719 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025068213-A1 | USE OF A MARKER SET FOR DETERMINING THE RISK OF HAVING OR DEVELOPING BLADDER CANCER | NUMARES AG (DE) | 2025-04-03 | — | — | WO | claimed |
| WO-2024151651-A1 | METHOD FOR TREATING NETOSIS-MEDIATED DISEASES | NATIONAL HEALTH RESEARCH INSTITUTES (TW) | 2024-07-18 | — | — | WO | claimed |
| WO-2022075354-A1 | A METHOD FOR OBTAINING AN INDEX FOR THE DIAGNOSIS OF ALZHEIMER'S DISEASE (AD) | OKINAWA INSTITUTE OF SCIENCE AND TECHNOLOGY SCHOOL CORPORATION (JP) | 2022-04-14 | — | — | WO | claimed |
| EP-3946353-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF ADCY5-RELATED DYSKINESIA | ASSISTANCE PUBLIQUE, HOPITAUX DE PARIS (FR) | 2022-02-09 | — | — | EP | claimed |
| US-20170362616-A1 | BIOSYNTHETIC PRODUCTION OF CAFFEINE | CODEXIS INC (US) | 2017-12-21 | — | — | US | claimed |
| EP-3223621-A1 | BIOSYNTHETIC PRODUCTION OF CAFFEINE | Codexis, Inc. (US) | 2017-10-04 | — | — | EP | claimed |
| EP-2603227-B1 | IMPROVED HEMATOPOIETIC STEM AND PROGENITOR CELL THERAPY | FATE THERAPEUTICS INC (US) | 2017-10-04 | — | — | EP | claimed |
| EP-3217984-A1 | CAFFEINE FOR THE TREATMENT OF MYOTONIC DYSTROPHY TYPE 1 AND TYPE 2 | Universitat de València (ES) | 2017-09-20 | — | — | EP | claimed |
| CN-107028936-A | Carotenoid particle and its application | IP科技有限公司 | 2017-08-11 | — | — | CN | claimed |
| US-20170049893-A1 | CAROTENOID PARTICLES AND USES THEREOF | IP SCIENCE LIMITED (GB) | 2017-02-23 | — | — | US | claimed |
| WO-1998014181-A1 | TREATMENT AND PREVENTION OF HEPATIC DISORDERS | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1998-04-09 | — | — | WO | claimed |
| EP-0508848-B1 | Cosmetic composition for combatting skin-ageing containing in association at least one retinoid and at least one dialkyl- or trialkylxanthine | OREAL (FR) | 1995-07-19 | — | — | EP | claimed |
| US-5399688-A | Caffeine recovery from activated carbon | JACOBS SUCHARD AG (CH) | 1995-03-21 | — | — | US | claimed |
| EP-0583498-A1 | Improved caffeine recovery from activated carbon | Jacobs Suchard AG (CH) | 1994-02-23 | — | — | EP | claimed |
| EP-0508848-A1 | Cosmetic composition for combatting skin-ageing containing in association at least one retinoid and at least one dialkyl- or trialkylxanthine | L'OREAL (FR) | 1992-10-14 | — | — | EP | claimed |
| US-4581359-A | FOR BRONCHOPULMONARY INSUFFUCIENCY | THE STATE OF OREGON ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF OREGON STATE UNIVERSITY (US) | 1986-04-08 | — | — | US | claimed |
| EP-0169236-A1 | CONTROLLED RELEASE LIQUID DOSAGE FORMULATIONS FOR PHARMACEUTICALS | BATTELLE DEVELOPMENT CORPORATION (US) | 1986-01-29 | — | — | EP | claimed |
| WO-1985003000-A1 | CONTROLLED RELEASE LIQUID DOSAGE FORMULATIONS FOR PHARMACEUTICALS | BATTELLE DEVELOPMENT CORPORATION (US) | 1985-07-18 | — | — | WO | claimed |
| EP-0045617-A2 | Pharmaceutical composition | Smith and Nephew Associated Companies p.l.c. (GB) | 1982-02-10 | — | — | EP | claimed |
| US-4189469-A | Pharmaceutical compositions | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-02-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170049893-A1 | CAROTENOID PARTICLES AND USES THEREOF | CHLSN, NPC1L1, LPL | ADORA2B 3903/4885ADORA2A 3376/4885ALDH1A1 4110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.